Experience in the treatment of metastatic and progressive renal cell cancer with sunitinib in Klaipeda University Hospital from 2008.04 till 2011.04.
Alvydas Česas Abstract Summary Renall- cell carcinoma is the most common cancer of the kidney. Every year about 120000 new kidney cancer cases are diagnosed, in Lithuania 600-700 new cases. Sunitinib is a novel multi-tyrosine kinase inhibitor. In Klaipėda university hospital were treated 47 patients with sunitinib malate. Our data was compared to historic treatment…